logo
logo
Haemonetics Corporation

Haemonetics Corporation

NYSE•HAE
CEO: Mr. Christopher A. Simon
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 1991-05-10
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
連絡先情報
125 Summer Street, Boston, MA, 02110, United States
781-848-7100
www.haemonetics.com
時価総額
$2.70B
PER (TTM)
15.4
27.9
配当利回り
--
52週高値
$87.32
52週安値
$47.32
52週レンジ
26%
順位21Top 7.6%
6.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2026 データ

売上高

$338.97M+0.00%
直近4四半期の推移

EPS

$0.96+0.00%
直近4四半期の推移

フリーCF

$87.22M+0.00%
直近4四半期の推移

2026 Q2 決算ハイライト

主なハイライト

Operating Income Jumps 22.9% Operating income reached $112.36M for six months, increasing 22.9% driven by pricing and lower restructuring costs.
Gross Margin Expands Significantly Gross margin improved to 59.7% from 53.2% year-over-year, reflecting strong pricing benefits across units.
Operating Cash Flow Surges Cash provided by operations totaled $128.72M, a massive increase from $21.40M last year period.
Net Income Shows Slight Growth Net income grew slightly 0.7% to $72.72M for six months, while basic EPS rose 7.0% to $1.52.

リスク要因

Revenue Declines 4.8% Total net revenues fell 4.8% to $648.71M, driven by Plasma transition and Whole Blood divestiture impacts.
Intangible Impairment Rises Intangible asset impairment charges increased significantly to $8.58M this period, up from $2.39M previously.
Plasma Revenue Drops Plasma net revenues decreased 7.0% to $255.26M due to North America customer transition impacts.
Contingent Consideration Liability Contingent consideration liability stands at $2.09M, based on Level 3 unobservable inputs and future performance milestones.

見通し

New Share Repurchase Program Board approved a new $500.0M share repurchase program through April 2028 to offset dilution impact.
Market Alignment Initiative New strategic initiative launched in May 2025 focuses on cost reduction and directing resources for growth.
2026 Notes Maturity Imminent $300.0M principal balance of 2026 Notes matures March 1, 2026; holders can convert until September 2025.
Strategic Investment Focus Company holds $73.7M investment in Vivasure Medical, expanding Hospital business unit portfolio strategically.

同業比較

売上高 (TTM)

Bausch Health Companies Inc.BHC
$10.03B
+5.9%
DENTSPLY SIRONA Inc.XRAY
$3.62B
-7.1%
Acadia Healthcare Company, Inc.ACHC
$3.27B
+4.6%

粗利益率 (最新四半期)

Acadia Healthcare Company, Inc.ACHC
96.4%
+0.1pp
Agios Pharmaceuticals, Inc.AGIO
87.0%
-4.3pp
Catalyst Pharmaceuticals, Inc.CPRX
82.9%
-2.1pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CON$3.06B18.051.2%0.0%
ITGR$2.99B34.55.2%38.6%
CPRX$2.90B13.326.4%0.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
0.8%
緩やかな成長
4四半期純利益CAGR
-8.3%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年5月6日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-Q - Q2 2026

    会計期末: 2025年9月27日|提出日: 2025年11月6日|
    売上高: $327.32M-5.3%
    |
    EPS: $0.81+22.7%
    予想を下回る
  • Form 10-Q - Q1 2026

    会計期末: 2025年6月28日|提出日: 2025年8月7日|
    売上高: $321.39M-4.4%
    |
    EPS: $0.71-5.3%
    予想を下回る
  • Form 10-K - FY 2025

    会計期末: 2025年3月29日|提出日: 2025年5月21日|
    売上高: $1.36B+4.0%
    |
    EPS: $3.31+42.7%
    予想を上回る
  • Form 10-Q - Q3 2025

    会計期末: 2024年12月28日|提出日: 2025年2月6日|
    売上高: $348.54M+3.7%
    |
    EPS: $0.75+21.0%
    予想を下回る
  • Form 10-Q - Q2 2025

    会計期末: 2024年9月28日|提出日: 2024年11月7日|
    売上高: $345.51M+8.6%
    |
    EPS: $0.66+34.7%
    予想を下回る
  • Form 10-Q - Q1 2025

    会計期末: 2024年6月29日|提出日: 2024年8月8日|
    売上高: $336.17M+8.0%
    |
    EPS: $0.75-7.4%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年3月30日|提出日: 2024年5月20日|
    売上高: $1.31B+12.0%
    |
    EPS: $2.32+2.2%
    予想を上回る
  • Form 10-Q - Q3 2024

    会計期末: 2023年12月30日|提出日: 2024年2月8日|
    売上高: $336.25M+10.1%
    |
    EPS: $0.62-4.6%
    予想を下回る